Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer

British Journal of Cancer

Volumn 104, Issue 2, 2011, Pages 316-323

  Papadaki, C ^a   Tsaroucha, E ^b   Kaklamanis, L ^c   Lagoudaki, E ^d   Trypaki, M ^a   Tryfonidis, K ^a,d   Mavroudis, D ^a,d   Stathopoulos, E ^d   Georgoulias, V ^a,d   Souglakos, J ^a,d  

^a UNIVERSITY OF CRETE   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c Department of Pathology   (Greece)

^d UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

BRCA1; NSCLC; taxanes; TSP1; TXR1

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; DOCETAXEL; GEMCITABINE; MESSENGER RNA; PROTEIN; TAXOL RESISTANCE PROTEIN 1; THROMBOSPONDIN 1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICRODISSECTION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; GENES, BRCA1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; REPRESSOR PROTEINS; RETROSPECTIVE STUDIES; RNA, MESSENGER; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 78751584929     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6606027     Document Type: Article

References (36)

1. Bartolucci R, Wei J, Sanchez JJ, Perez-Roca L, Chaib I, Puma F, Farabi R, Mendez P, Roila F, Okamoto T, Taron M, Rosell R (2009) XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer 10: 47-52
2. Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, Georgoulias V, Rosell R, Souglakos J (2008) Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One 3: e3695
3. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, Palamidas P, Vlachonikolis I (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357: 1478-1484
4. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T (2000a) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 97: 2904-2909
5. Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T (2000b) Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 19: 3078-3085
6. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118-17125
7. Gottesman MM, Ling V (2006) The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580: 998-1009
8. Guerrero D, Guarch R, Ojer A, Casas JM, Ropero S, Mancha A, Pesce C, Lloveras B, Garcia-Bragado F, Puras A (2008) Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma. BJU Int 102: 747-755
9. Harsch M, Bendrat K, Hofmeier G, Branscheid D, Niendorf A (2001) A new method for histological microdissection utilizing an ultrasonically oscillating needle: demonstrated by differential mRNA expression in human lung carcinoma tissue. Am J Pathol 158: 1985-1990
10. Husain A, He G, Venkatraman ES, Spriggs DR (1998) BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichlor-oplatinum(II). Cancer Res 58: 1120-1123
11. Ioachim E, Michael MC, Salmas M, Damala K, Tsanou E, Michael MM, Malamou-Mitsi V, Stavropoulos NE (2006) Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer 6: 140
12. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249
13. Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW, Kim JH (2010) The prognostic significance of ERCC1, BRCA1, XRCC1, and [beta]III-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer 68: 478-483
14. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100: 1282-1293
15. Kennedy RD, Quinn JE, Johnston PG, Harkin DP (2002) BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 360: 1007-1014
16. Kim HT, Lee JE, Shin ES, Yoo YK, Cho JH, Yun MH, Kim YH, Kim SK, Kim HJ, Jang TW, Kwak SM, Kim CS, Ryu JS (2008) Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J Clin Oncol 26: 5972-5979
17. Lafarge S, Sylvain V, Ferrara M, Bignon YJ (2001) Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20: 6597-6606
18. Lih CJ, Wei W, Cohen SN (2006) Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev 20: 2082-2095
19. Lotti LV, Ottini L, D'Amico C, Gradini R, Cama A, Belleudi F, Frati L, Torrisi MR, Mariani-Costantini R (2002) Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer 35: 193-203
20. Manna PP, Dimitry J, Oldenborg PA, Frazier WA (2005) CD47 augments Fas/CD95-mediated apoptosis. J Biol Chem 280: 29637-29644
21. Mateo V, Lagneaux L, Bron D, Biron G, Armant M, Delespesse G, Sarfati M (1999) CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia. Nat Med 5: 1277-1284
22. Mullan PB, McWilliams S, Quinn J, Andrews H, Gilmore P, McCabe N, McKenna S, Harkin DP (2001) Uncovering BRCA1-regulated signalling pathways by microarray-based expression profiling. Biochem Soc Trans 29: 678-683
23. Neal CP, Garcea G, Doucas H, Manson MM, Sutton CD, Dennison AR, Berry DP (2006) Molecular prognostic markers in resectable colorectal liver metastases: a systematic review. Eur J Cancer 42: 1728-1743
24. Papadaki C, Mavroudis D, Trypaki M, Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki E, Georgoulias V, Souglakos J (2009) Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. Clin Cancer Res 15: 3827-3833
25. Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GK, Mullan PB, Johnston PG, Wilson RH, Harkin DP (2007) BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13: 7413-7420
26. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 63: 6221-6228
27. Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, Chaib I, Provencio M, Domine M, Sala MA, Jimenez U, Diz P, Barneto I, Macias JA, de Las PR, Catot S, Isla D, Sanchez JM, Ibeas R, Lopez-Vivanco G, Oramas J, Mendez P, Reguart N, Blanco R, Taron M (2009) Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 4: e5133
28. Rosell R, Scagliotti G, Danenberg KD, Lord RV, Bepler G, Novello S, Cooc J, Crino L, Sanchez JJ, Taron M, Boni C, De MF, Tonato M, Marangolo M, Gozzelino F, Di CF, Rinaldi M, Salonga D, Stephens C (2003) Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22: 3548-3553
29. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, Mendez P, Chaib I, Perez-Roca L, Szymanowska A, Rzyman W, Puma F, Kobierska-Gulida G, Farabi R, Jassem J (2007) BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2: e1129
30. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98 (Pubitemid 34438899)
31. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, Kerbel RS (2005) Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 7: 101-111
32. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J (2004) BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13: 2443-2449
33. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
34. Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T, Liu B (2008) ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 8: 97
35. Yamaguchi M, Sugio K, Ondo K, Yano T, Sugimachi K (2002) Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer. Lung Cancer 36: 143-150
36. Yoo GH, Piechocki MP, Ensley JF, Nguyen T, Oliver J, Meng H, Kewson D, Shibuya TY, Lonardo F, Tainsky MA (2002) Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin Cancer Res 8: 3910-3921